Clinical Trial Update: PF-00489791 For The Treatment Of Raynaud's [Phase 2]

View source ↗

Summary

Pfizer's PF-00489791 completed a Phase 2 trial for Raynaud's disease and peripheral vascular disease, with results posted in May 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Vascular Disease
• Raynaud Disease

Drugs mentioned

• PF-00489791 (PF-00489791)

Snippet

Sponsor: Pfizer | Conditions: Raynaud's Disease, Peripheral Vascular Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-05-16